REVEAL GENOMICS®️ ANNOUNCES RESEARCH COLLABORATION IN HER2+ BREAST CANCER
Barcelona, Spain (ots/PRNewswire) - - The agreement with Dana-Farber Cancer Institute consists of using HER2DX®️ to analyze tumor samples from more than 500 patients with early-stage HER2+ breast cancer across three clinical trials (APT, ATEMPT, and DAPHNE). - The three completed studies were essential in establishing new anti-HER2-based treatment strategies for ...